Last reviewed · How we verify

Efavirenz plus Lamivudine/Zidovudine

University of Cologne · Phase 3 active Small molecule

Efavirenz plus Lamivudine/Zidovudine is a Antiretroviral combination therapy (NNRTI + NRTIs) Small molecule drug developed by University of Cologne. It is currently in Phase 3 development for HIV-1 infection.

This combination inhibits HIV reverse transcriptase through three complementary mechanisms: efavirenz as a non-nucleoside reverse transcriptase inhibitor and lamivudine/zidovudine as nucleoside reverse transcriptase inhibitors.

This combination inhibits HIV reverse transcriptase through three complementary mechanisms: efavirenz as a non-nucleoside reverse transcriptase inhibitor and lamivudine/zidovudine as nucleoside reverse transcriptase inhibitors. Used for HIV-1 infection.

At a glance

Generic nameEfavirenz plus Lamivudine/Zidovudine
SponsorUniversity of Cologne
Drug classAntiretroviral combination therapy (NNRTI + NRTIs)
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Efavirenz binds directly to HIV reverse transcriptase and blocks its catalytic activity. Lamivudine and zidovudine are nucleoside analogs that get incorporated into the growing viral DNA chain, causing chain termination and preventing viral replication. Together, these agents target reverse transcriptase through different mechanisms to suppress HIV viral load.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Efavirenz plus Lamivudine/Zidovudine

What is Efavirenz plus Lamivudine/Zidovudine?

Efavirenz plus Lamivudine/Zidovudine is a Antiretroviral combination therapy (NNRTI + NRTIs) drug developed by University of Cologne, indicated for HIV-1 infection.

How does Efavirenz plus Lamivudine/Zidovudine work?

This combination inhibits HIV reverse transcriptase through three complementary mechanisms: efavirenz as a non-nucleoside reverse transcriptase inhibitor and lamivudine/zidovudine as nucleoside reverse transcriptase inhibitors.

What is Efavirenz plus Lamivudine/Zidovudine used for?

Efavirenz plus Lamivudine/Zidovudine is indicated for HIV-1 infection.

Who makes Efavirenz plus Lamivudine/Zidovudine?

Efavirenz plus Lamivudine/Zidovudine is developed by University of Cologne (see full University of Cologne pipeline at /company/university-of-cologne).

What drug class is Efavirenz plus Lamivudine/Zidovudine in?

Efavirenz plus Lamivudine/Zidovudine belongs to the Antiretroviral combination therapy (NNRTI + NRTIs) class. See all Antiretroviral combination therapy (NNRTI + NRTIs) drugs at /class/antiretroviral-combination-therapy-nnrti-nrtis.

What development phase is Efavirenz plus Lamivudine/Zidovudine in?

Efavirenz plus Lamivudine/Zidovudine is in Phase 3.

What are the side effects of Efavirenz plus Lamivudine/Zidovudine?

Common side effects of Efavirenz plus Lamivudine/Zidovudine include Dizziness and CNS effects (efavirenz), Rash, Nausea, Headache, Lipodystrophy (zidovudine), Anemia (zidovudine).

What does Efavirenz plus Lamivudine/Zidovudine target?

Efavirenz plus Lamivudine/Zidovudine targets HIV reverse transcriptase and is a Antiretroviral combination therapy (NNRTI + NRTIs).

Related